IMMUNOVANT INC. - CO
29.40
07-October-24 15:59:58
15 minutes delayed
Stocks
-1.11
-3.64%
Today's range
28.92 - 30.58
ISIN
N/A
Source
NASDAQ
-
Immunovant Provides Update on Graves’ Disease Development Program
09 Sep 2024 03:55:00 By Nasdaq GlobeNewswire
-
Immunovant to Host Graves’ Disease Program Update on September 9, 2024
05 Sep 2024 06:30:00 By Nasdaq GlobeNewswire
-
06 Aug 2024 16:05:01 By Nasdaq GlobeNewswire
-
29 May 2024 16:01:00 By Nasdaq GlobeNewswire
-
Immunovant Awarded U.S. Patent for IMVT-1402
12 Mar 2024 07:30:04 By Nasdaq GlobeNewswire
-
12 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
-
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
20 Dec 2023 16:30:00 By Nasdaq GlobeNewswire
-
28 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
-
Immunovant to Present at Upcoming Investor Conferences
13 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
-
09 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
-
02 Oct 2023 16:52:02 By Nasdaq GlobeNewswire
-
Immunovant Announces Pricing of $450 Million Common Stock Financing
27 Sep 2023 23:41:51 By Nasdaq GlobeNewswire
-
Immunovant Announces Proposed Offering of $300 Million of Common Stock
26 Sep 2023 17:00:00 By Nasdaq GlobeNewswire
-
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
26 Sep 2023 06:00:00 By Nasdaq GlobeNewswire
-
25 Sep 2023 23:01:32 By Nasdaq GlobeNewswire
-
10 Aug 2023 07:00:01 By Nasdaq GlobeNewswire
-
22 May 2023 07:00:00 By Nasdaq GlobeNewswire
-
03 Feb 2023 07:00:00 By Nasdaq GlobeNewswire
-
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
07 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >